A method for coating a medical implant applies at least one coating to at least one surface of the implant by plasma polymerization. The implant has pores sized in the nanometer range. The method stabilizes the pores. The plasma polymerization is conducted in the presence of a coating gas and oxygen. A coating parameter can be selected so that a rough surface of the implant is coated. An implant includes a membrane having pores sized in the nanometer range. A surface of the implant is at least partially coated with a plasma polymer. The interior of the pores is uncoated.

Provided is a use for a peptide in surface-treating a medical device or medical material to be used in contact with blood, with which it is possible to obtain a medical device or medical material that can achieve highly efficient vascular endothelialization through the use of a peptide uniquely binding to vascular endothelial cells. Also provided are: a peptide suitable for use in said surface treatment; a method for producing a medical device or medical material surfaced-treated with said peptide and to be used in contact with blood; and a surface treatment agent including said peptide, said agent to be used in surface-treating a medical device or medical material to be used in contact with blood. In the present invention, a medical device or medical material is surface-treated using a peptide that includes any one of ten specific amino acid sequences and uniquely binds to the surface of endothelial progenitor cells.

A medical textile product includes a textile substrate having opposed first and second surfaces with the textile substrate including a textile construction of one or more yarns. The second surface includes a coating of a substantially water-insoluble, non-porous elastomeric sealant. The one or more yarns at the first surface are pre-treated with a removable composition, such that the water-insoluble elastomeric sealant encapsulates a portion of fibers of the one or more yarns at the second surface of the textile substrate. The textile substrate is substantially impermeable to fluid. The first surface is substantially free of the substantially water-insoluble elastomeric sealant. The textile substrate may be a non-tubular substrate, such as a planar sheet, a shaped sheet, and a tape, or a tubular substrate, such as a cylindrical conduit, a tubular conduit, a Y-shaped, a T-shaped conduit, a multi-channel conduit, and a bulbous shaped conduit.

Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGFβ inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

A method and a medical elongate body are configured to prevent stagnation or turbulence of blood flow in a recess of a rugged pattern formed in a blood vessel due to bulging of a blood vessel wall at a lesion part of the blood vessel. The method involves partitioning an inside of the blood vessel into upstream and downstream sides of the recess, and introducing gel into the recess to at least partially fill the recess. A blood vessel lumen forming method and medical elongate body to form such a lumen are other aspects of the disclosure and involve introducing gel into the recess to at least partially fill the recess with the gel, and drilling the gel to remove at least some of the gel to form a passage and secure blood flow in the blood vessel.

The present invention provides valve prostheses adapted to be initially crimped in a narrow configuration suitable for catheterization through body ducts to a target location and adapted to be deployed by exerting substantially radial forces from within by means of a deployment device to a deployed state in the target location.

The method for producing a three-dimensional artificial tissue is a method in which a three-dimensional artificial tissue extending in a predetermined direction is produced. The method includes: preparing a device including a culture tank having a culturing space surrounded by sidewalls, and a flow channel-forming member that penetrates through the sidewalls that face each other and is suspended in the culturing space along a predetermined direction; culturing cells in the culturing space and thereby forming a three-dimensional artificial tissue through which the flow channel-forming member penetrates; and removing the flow channel-forming member from the three-dimensional artificial tissue and thereby forming a perfusion flow channel that penetrates through the three-dimensional artificial tissue.

Devices, systems, and methods are provided including a structure having one or more surfaces configured for internal use within a patient's body and one or more therapeutic compositions comprising one or more active substances including a direct factor Xa inhibitor, and a direct factor IIa inhibitor disposed in or on the structure. The structure is configured to be positioned adjacent an injury site in the patient's body. The one or more active substances optionally include an anti-proliferative agent. The therapeutic composition is formulated to release the one or more active substances to the injury site to provide one or more of inhibit clot formation, promote clot dissolution, inhibit or dissolute inflammation, inhibit vessel injury, increase time before clotting, and/or inhibit cell proliferation.

Disclosed is a method for preparing a nitric oxide-generating adherent coating, comprising: preparing a buffer solution containing polyphenol compounds, organic selenium or sulfur compounds and soluble copper salts; then contacting a base material with the solution, and washing and drying to obtain a target product. The nitric oxide-generating material prepared by the method can be used for any medical device, such as an intravascular stent, or materials and any complex-shaped base material, and has the capability of scavenging free radicals and catalyzing RSNO to produce nitrogen monoxide, and also has a response function of reduced glutathione (GSH), an antimicrobial function and all the physiological functions possessed by nitrogen monoxide.

A gallium silica glass composition is described. The glass can be used in variety of biomedical applications